SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1755)3/9/2016 11:28:00 PM
From: mokelumne river  Read Replies (1) | Respond to of 2026
 
I agree that there was no new news to convey on RayVa. I just wanted some mention in what amounts to a state of the company conference call that RayVa was one of the three drugs in the Apricus pipeline. A single sentence would have done it. However, not a big deal.



To: phoenix_rising who wrote (1755)3/11/2016 1:26:30 PM
From: mokelumne river  Respond to of 2026
 
PR, I read the transcript and RayVa was indeed mentioned by Cath in her penultimate closing sentence. I missed that.

On Fis, despite the positive feelings that most seem to sense, the study is double blind/placebo controlled. So nobody at this time can know the results. In other words, let us pray.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News